Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation

Smith Giri, Shadi Hamdeh, Vijaya R Bhatt, James K Schwarz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.

Original languageEnglish (US)
Pages (from-to)508-514
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Receptor Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Mutation
Idarubicin
Cytarabine
Multicenter Studies
sorafenib

ASJC Scopus subject areas

  • Oncology

Cite this

@article{6ea61fee423b42b2a350a862310a33b9,
title = "Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation",
abstract = "Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.",
author = "Smith Giri and Shadi Hamdeh and Bhatt, {Vijaya R} and Schwarz, {James K}",
year = "2015",
month = "5",
day = "1",
doi = "10.6004/jnccn.2015.0070",
language = "English (US)",
volume = "13",
pages = "508--514",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation

AU - Giri, Smith

AU - Hamdeh, Shadi

AU - Bhatt, Vijaya R

AU - Schwarz, James K

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.

AB - Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.

UR - http://www.scopus.com/inward/record.url?scp=84984551804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984551804&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0070

DO - 10.6004/jnccn.2015.0070

M3 - Article

VL - 13

SP - 508

EP - 514

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -